Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 04, 2025 | June 06, 2025 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Chief Medical Officer | August 12, 2025 | August 15, 2025 |
| ELI LILLY & CoLLY · Entity 2794 | EVP & Pres, Lilly Neuroscience | December 31, 2025 | January 06, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.15 · Expires 2035-06-04 | Direct | 33,662 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 33,662 · Balance 33,662 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Denali Therapeutics Inc.
Report date August 12, 2025 · Filed August 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,585 |
Last balance in matching sequence
After 2025-08-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-08-12 · Sale · Disposed 2,937 · Balance 217,391 F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 128,405 Unvested RSUs. Row 2 · 2025-08-13 · Sale · Disposed 806 · Balance 216,585 F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024. F3: Includes 128,405 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 183,219 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 183,219 F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,000 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 25,000 F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 128,405 Unvested RSUs.
F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
ELI LILLY & Co
Report date December 31, 2025 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-31 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028.
F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 4,545 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 4,545 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 8,558 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,558 F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 19,619 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.66 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 39,515 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:24 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 4,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001724605-26-000007 · wk-form4_1780950258.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,545 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 00:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 806 | $14.64 | $11,799.84 |
DisclosureSEC source: 0001714899-25-000176 · wk-form4_1755217980.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,585 F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024. F3 · balance_after: Includes 128,405 Unvested RSUs. Read SEC document |
| August 12, 2025 Filed Aug 15, 2025 00:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,937 | $13.58 | $39,884.46 |
DisclosureSEC source: 0001714899-25-000176 · wk-form4_1755217980.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,391 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 128,405 Unvested RSUs. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 44,655 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-25-000153 · wk-form4_1754602468.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 44,655 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 44,655 | $0.68 | $30,365.40 |
DisclosureSEC source: 0001714899-25-000153 · wk-form4_1754602468.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 134,030 Unvested RSUs. Read SEC document |
| July 31, 2025 Filed Aug 1, 2025 00:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 5,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000088 · wk-form4_1754008916.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,558 F2 · shares: Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| July 31, 2025 Filed Aug 1, 2025 00:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 2,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000088 · wk-form4_1754008916.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,752 F1 · shares: Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083051 · ownership.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 01:26 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,907 | $20.81 | $60,494.67 |
DisclosureSEC source: 0001714899-25-000051 · wk-form4_1736385991.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,673 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F3 · balance_after: Includes 134,030 Unvested RSUs. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:26 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 12,255 | $20.22 | $247,796.10 |
DisclosureSEC source: 0001714899-25-000051 · wk-form4_1736385991.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,580 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 134,030 Unvested RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 162,540 | $0.00 Strike: $21.26 | $0.00 |
DisclosureSEC source: 0001714899-25-000026 · wk-form4_1736294172.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,540 Underlying: Common Stock · 162,540 shares Expires 2035-01-02 F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 54,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000026 · wk-form4_1736294172.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,835 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 141,530 Unvested RSUs. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 17,845 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-24-000235 · wk-form4_1732743876.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,155 Underlying: Common Stock · 17,845 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 17,845 | $0.68 | $12,134.60 |
DisclosureSEC source: 0001714899-24-000235 · wk-form4_1732743876.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,907 | $24.96 | $147,438.72 |
DisclosureSEC source: 0001714899-24-000194 · wk-form4_1724357642.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,810 F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.84 to $25.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,098 | $24.41 | $344,132.18 |
DisclosureSEC source: 0001714899-24-000194 · wk-form4_1724357642.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,717 F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.84 to $24.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,453 | $23.79 | $58,356.87 |
DisclosureSEC source: 0001714899-24-000194 · wk-form4_1724357642.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,815 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.62 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,337 | $22.89 | $53,493.93 |
DisclosureSEC source: 0001714899-24-000176 · wk-form4_1723752552.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,268 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · balance_after: Includes 123,810 RSUs. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:47 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 23,114 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0000950170-24-070788 · ownership.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,114 Underlying: Common Stock · 23,114 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 39,515 | Not disclosed Strike: $20.66 | Not disclosed |
DisclosureSEC source: 0000950170-24-042606 · ownership.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,515 shares Expires 2030-06-04 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,619 | Not disclosed Strike: $17.24 | Not disclosed |
DisclosureSEC source: 0000950170-24-042606 · ownership.xml · derivative · entry 3 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,619 shares Expires 2031-06-07 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,222 | Not disclosed Strike: $13.35 | Not disclosed |
DisclosureSEC source: 0000950170-24-042606 · ownership.xml · derivative · entry 2 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,222 shares Expires 2032-05-17 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,407 | Not disclosed Strike: $3.69 | Not disclosed |
DisclosureSEC source: 0000950170-24-042606 · ownership.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,407 shares Expires 2033-05-09 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 02:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,405 | $17.79 | $24,994.95 |
DisclosureSEC source: 0001714899-24-000060 · wk-form4_1708049673.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,605 F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.55 to $17.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price F3 · balance_after: Includes 129,435 RSUs. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 02:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,784 | $17.29 | $48,135.36 |
DisclosureSEC source: 0001714899-24-000060 · wk-form4_1708049673.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,010 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 129,435 RSUs. Read SEC document |
| January 10, 2024 Filed Jan 13, 2024 01:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,668 | $19.02 | $88,785.36 |
DisclosureSEC source: 0001714899-24-000040 · wk-form4_1705108724.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,794 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $18.61 to $19.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 136,904 RSUs. F4 · balance_after: Reflects 15,558 shares previously disclosed as held indirectly; but have been determined to be held directly. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,972 | $19.43 | $193,755.96 |
DisclosureSEC source: 0001714899-24-000038 · wk-form4_1704846922.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 198,777 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.35 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 25,530 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 161,160 | $0.00 Strike: $20.33 | $0.00 |
DisclosureSEC source: 0001714899-24-000009 · wk-form4_1704495415.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,160 Underlying: Common Stock · 161,160 shares Expires 2034-01-02 F6 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 53,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000009 · wk-form4_1704495415.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,434 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 136,904 RSU's as of January 4, 2024. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,522 | $23.22 | $58,560.84 |
DisclosureSEC source: 0001714899-23-000136 · wk-form4_1692999010.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 182,809 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2022. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,478 | $22.60 | $56,002.80 |
DisclosureSEC source: 0001714899-23-000135 · wk-form4_1692822872.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 185,331 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.55 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,000 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,768 | $23.79 | $65,850.72 |
DisclosureSEC source: 0001714899-23-000125 · wk-form4_1692224392.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 182,809 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2023. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,857 | $24.15 | $68,996.55 |
DisclosureSEC source: 0001714899-23-000122 · wk-form4_1692047539.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 185,577 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.99 to $24.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,625 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:49 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 16,532 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0000950170-23-027040 · ownership.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,532 Underlying: Common Stock · 16,532 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| May 10, 2023 Filed May 12, 2023 17:48 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 78,407 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-23-029181 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,407 Underlying: Common Stock · 78,407 shares Expires 2033-05-09 F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,476 | $29.40 | $43,394.40 |
DisclosureSEC source: 0001714899-23-000033 · wf-form4_167666882057002.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 182,809 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 00:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,548 | $30.10 | $76,694.80 |
DisclosureSEC source: 0001714899-23-000025 · wf-form4_167641959398926.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 184,285 F3 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.90 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,468 RSUs held by the Reporting Person. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 00:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 818 | $29.80 | $24,376.40 |
DisclosureSEC source: 0001714899-23-000025 · wf-form4_167641959398926.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 179,365 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,521 | $30.88 | $46,968.48 |
DisclosureSEC source: 0001714899-23-000021 · wf-form4_167607072949570.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 180,183 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.80 to $31.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 4,250 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 21:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,459 | $28.48 | $41,552.32 |
DisclosureSEC source: 0001714899-23-000017 · wf-form4_167338746261232.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 177,454 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 02:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,451 | $28.67 | $41,600.17 |
DisclosureSEC source: 0001714899-23-000016 · wf-form4_167331860319501.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,913 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,636 | $28.44 | $74,967.84 |
DisclosureSEC source: 0001714899-23-000016 · wf-form4_167331860319501.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 180,364 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,500 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,913 | $28.69 | $83,573.97 |
DisclosureSEC source: 0001209191-23-002184 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 175,500 F4 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.48 to $28.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,750 RSUs held by the Reporting Person. F6 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 123,360 | $0.00 Strike: $27.63 | $0.00 |
DisclosureSEC source: 0001209191-23-002184 · doc4.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,360 Underlying: Common Stock · 123,360 shares Expires 2033-01-02 F8 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 41,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002184 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,967 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 138,557 RSUs. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,750 RSUs held by the Reporting Person. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 10,391 | $0.00 Strike: $55.58 | $0.00 |
DisclosureSEC source: 0000899243-22-030278 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Underlying: Common Stock · 10,391 shares Expires 2032-09-01 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 22:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,424 | $31.98 | $77,519.52 |
DisclosureSEC source: 0001714899-22-000130 · wf-form4_166146541259069.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 170,663 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,576 | $33.22 | $85,574.72 |
DisclosureSEC source: 0001714899-22-000126 · wf-form4_166128752453768.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 173,087 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.11 to $33.39 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 23:22 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000125 · wf-form4_166026015800698.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,597 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on August 9, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider ofthe Issuer through each such date. F2 · balance_after: Includes 110,187 restricted stock units. Read SEC document |
| May 18, 2022 Filed May 20, 2022 18:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 24,222 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001209191-22-031133 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,222 Underlying: Common Stock · 24,222 shares Expires 2032-05-17 F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.